Since the discovery of a linkage between GRKs and cardiovascular disease including hypertension and heart failure, GRKs—especially GRK2 and GRK4—have been considered pharmaceutical targets for the treatment of cardiovascular disease. Here, GRK4 is linked to heart failure.